- Home
- STRO vs DSM Comparison
STRO vs DSM Comparison
Compare STRO & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STRO | DSM |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.8M | 298.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | STRO | DSM |
|---|---|---|
| Price | $15.83 | $5.34 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | ★ 266.5K | 107.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,419,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $5.41 |
| 52 Week High | $43.85 | $6.30 |
Technical Indicators
Market Signals| Indicator | STRO | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 29.75 | N/A |
| Support Level | $10.34 | N/A |
| Resistance Level | $17.33 | N/A |
| Average True Range (ATR) | 0.95 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 22.02 | 0.00 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.